Immix intends to use the net proceeds from this offering, together with its existing cash and cash equivalents to fund NXC-201 development and for working capital and general corporate purposes. Immix ...

Tazemetostat is a first-in-class methyltransferase inhibitor of EZH2 developed by Epizyme, an Ipsen company. HUTCHMED entered into a strategic collaboration with Epizyme to research, develop, ...

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today ...

Updated clinical data presented at ASH show robust efficacy, rapid onset of remission, high incidence of MRD 1 -negativity, and an encouraging survival signal with ICT01 in combination with ...

Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, Associate Professor at the David Geffen School of Medicine, University of ...

A webcast of the conference call can be accessed by visiting “Investor Events” on the investor relations section of the Wave Life Sciences website: ...

The publication, titled “Prime Editing for p47-phox Chronic Granulomatous Disease,” reports initial data for two patients treated in the Phase 1/2 trial of PM359, which was designed to assess safety, ...

Findings further strengthen rationale for ongoing global Phase 3 TERZO study in nodal TFH lymphoma. BERKELY HEIGHTS, N. J., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( ), an integrated ...

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first ...

Mixed chimerism or relapses following TSC-101 infusions were found to be significantly associated with greater ex vivo expansion of TCR-T cells during the manufacturing process. A new commercial-ready ...

Broad tumor coverage Developed with our AI-Immunology™ platform, EVX-04 targets non-conventional ERV tumor antigens from the dark genome. These antigens are selectively expressed in specific tumors ...

Translational analyses show stronger immune fitness and a more immunocompetent TME when CARVYKTI® is used earlier in the treatment journey Eighty percent of as-treated patients in CARTITUDE-4 with ...